Incidence of hypokalemia during therapy with abirateron acetate - real clinical practice data (CROSBI ID 734146)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Vazdar, Ljubica ; Linarić, Petra ; Pavlović, Mirjana ; Tečić Vuger, Ana ; Šeparović, Robert ; Jurić, Andreja
engleski
Incidence of hypokalemia during therapy with abirateron acetate - real clinical practice data
Abirateron acetate (AA) selectively inhibits the CYP17 enzyme resulting in a decrease in androgen synthesis in the adrenal glands, testicles and prostate tissue. Inhibition of CYP17 reduces serum cortisol levels and increases ACTH secretion through negative feedback loop, which can lead to mineralocorticoid excess and cause hypokalemia, fluid retention and hypertension. Results show that in real clinical practice, AA therapy with prednisone coadministration does not lead to a significant suppression of serum cortisol levels and recurrent meneralocorticoid excess. On the other hand, a possible influence on the low incidence of hypokalemia is an angiotensin converting enzyme inhibitor (ACEi) therapy that was present in 13 (36%) patients due to comorbidity. In view of possible more severe forms of hypokalemia, especially in patients after docetaxel therapy and coadministration of ACEi and/or diuretics, serum potassium value should be monitored according to recommendations.
abirateron acetate, metastatic castration-resistant prostate cancer, hypokalemia
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
55-55.
2022.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
Libri oncologici : Croatian journal of oncology
0300-8142
2584-3826
Podaci o skupu
Nepoznat skup
poster
29.02.1904-29.02.2096